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Abstract
Background: Herpes zoster (HZ) has a significant negative effect on the productive work life of individuals, and has
been shown to be responsible for cases of absenteeism, presenteeism and decreased work effectiveness. The aim
of this study was to evaluate health utility scores and associated predictors in an actively employed population of
Herpes Zoster (HZ) patients with and without work time loss (WTL).
Methods: This was a pooled analysis of the prospective, observational MASTER cohort studies, conducted in 8
countries across North America, Latin America and Asia. A total of 428 HZ patients engaged in full or part time work
were included. WTL, defined as missing≥ 1 partial or full work day, and work effectiveness, reported on a scale of
0–100%, were evaluated with the Work and Productivity Questionnaire (WPQ). The Pearson product–moment
correlation was used to assess the correlation between work effectiveness and HRQoL. Mixed models with repeated
measures assessed the relationship between HZ-related WTL over a 6-month follow-up period, and HRQoL, as
evaluated by the EQ-5D. Additional predictors of HRQoL were also identified.
Results: Overall, 57.7% of respondents reported WTL. Mean (SD) percent work effectiveness of patients in the WTL
group was significantly lower compared to non-WTL (NWTL) patients at baseline [50.3 (31.6) vs. 71.4 (27.8); p < 0.001].
Patients in the WTL group also reported lower health utility scores at baseline and overall than their NWTL
counterparts, with WTL identified as an independent negative predictor of both the EQ-5D summary scores and the
EQ-5D VAS (p < 0.001). Decrease in work effectiveness was negatively associated with HRQoL overall (p < 0.001).
Predictors of lower HRQoL were worst Zoster Brief Pain Inventory (ZBPI) pain score, the presence of HZ complications
and country income (predictor of EQ-5D VAS only).
Conclusions: HZ adversely impacts the work and productive life of actively employed individuals. In turn, HZ-related
reductions in work effectiveness and work time are associated with a negative effect on HRQoL.
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Background
HZ or shingles is caused by the reactivation of the
varicella zoster virus (VZV), for which primary infec-
tion manifests as chickenpox, or varicella. The esti-
mated lifetime risk for the development of HZ is
approximately 30% [1–3]. Rash onset, the typical clin-
ical feature of HZ, is characterized by a unilateral,
dermatomal rash with vesicular lesions that usually
heal within 2–4 weeks [4]. Pain during this phase,
which ranges from moderate-to-severe in the majority
of patients [5], negatively impacts functional status
and QoL with greater acute pain burden significantly
associated with poorer physical role, social function-
ing, and greater emotional distress [5–8]. HZ has also
been shown to be responsible for cases of absentee-
ism, presenteeism (defined as attending work while
sick) and decreased work effectiveness [9–11], with
combined work loss varying significantly by disease
severity [10]. Consequently, HZ has a significant
negative effect on the productive work life of individ-
uals; consideration of this effect on work and prod-
uctivity therefore contributes to the cost-effectiveness
of HZ therapeutic interventions, specifically those
aiming at preventing VZV reactivation.
However, the true cost-effectiveness of therapeutic
interventions for HZ may be underestimated. This is
emphasized by discrepancies in guidelines for cost-
effectiveness analysis, which differ as to whether work
time loss should be included in the numerator of the
incremental cost-effectiveness ratio (ICER), or as an
implicit consideration of health state valuations,
which are contained in the denominator of the ICER.
This is due to the fact that it is unclear whether or
not people actually take into account the effect of
disease on their ability to work, and the resulting lost
wages, when evaluating health states [12–14]. The
Panel on Cost-Effectiveness in Health and Medicine
have nevertheless recently put forth revised recom-
mendations advocating for the inclusion of these ef-
fects in the numerator in the ICER [15].
The MASTER (Monitoring and Assessing Shingles
Through Education and Research) studies, were
prospective cohort studies conducted in 8 countries
[16–19], which assessed Herpes Zoster (HZ)-related
burden of illness, including pain, health related qual-
ity of life (HRQoL), health care resource utilisation
(HCRU), and associated cost. Using data from these
studies, the aim of this pooled analysis was to exam-
ine the association of HZ-related work time loss, or
HZ-related work productivity loss, with HRQoL, to
evaluate whether or not patients with work time loss
have lower health utility scores than those without,
and to identify predictors of HRQoL in an active
population of HZ patients.
Methods
Study design
This is a pooled analysis of the MASTER studies con-
ducted in 8 countries, which shared the same design and
were conducted using similar methodology [16–19]. The
objectives of the MASTER study were to measure HZ-
related burden of illness, HRQoL, health care resource
utilisation (HCRU), and out of pocket costs. Among the
1477 patients enrolled overall, 428 were engaged in full
or part time work (active population) and were, thus, in-
cluded in the current analysis, with the following geo-
graphic distribution: Latin America (n = 128), consisting
of Argentina (n = 37), Brazil (n = 36), Costa Rica (n = 6),
and Mexico (n = 49); North America, consisting of
Canada (n = 160); and Asia (n = 140), consisting of Korea
(n = 45), Taiwan (n = 49), and Thailand (n = 46).
Patient population
Patients eligible for cohort inclusion were either male or
female patients ≥ 50 years of age with HZ rash or re-
sidual HZ-associated pain, defined as pain persisting
subsequent to rash healing. In addition, in order to be
included in this analysis, patients had to belong to the
active population (actively employed in full or part time
work). Incident cases were defined as patients recruited
from the offices of general practitioners or specialists for
a current HZ episode (rash onset or start of pain) with a
duration of ≤ 7 days; prevalent cases were defined as pa-
tients enrolled experiencing a HZ episode which had
lasted longer than 7 days, with the onset of rash re-
corded in medical records. Key exclusion criteria were
the presence of any medical condition that, in the opin-
ion of the treating physician, could interfere with the
evaluations required by the study, and patient and/or
family member or primary caregiver refusal to sign in-
formed consent.
Treatment and follow-up
In accordance with the observational nature of the stud-
ies, any treatment of the HZ-episode was based on the
judgement of the treating physician. After the baseline
assessment at Day 0, patients were followed for a max-
imum of 6 months. Regardless of the phase of disease at
the time of enrolment, 9 follow-up assessments were
recommended at Days 7, 14, 21, 30, 60, 90, 120, 150 and
180, to a total of 10 visits, with the exception of Korea
and Taiwan, in which prevalent cases were assessed at
every month after the baseline visit, for a total of 7 visits
overall. The baseline (Day 0) assessment was conducted
at the physician’s office, and follow-up assessments were
conducted though self-administered questionnaires. At
baseline, information regarding the patient’s immune
status, pain-related medical history, demographics,
current medications, and characteristics of the current
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HZ-episode, was collected. The outcome measures de-
scribed in the following section were evaluated at each
patient assessment.
Pooled analysis outcome measures
Work productivity and work time loss
Work productivity of patients and/or caregivers was mea-
sured at every patient assessment irrespective of the pres-
ence of HZ rash and/or pain using a simple descriptive,
self-administered, standardized questionnaire, the Work
and Productivity Questionnaire (WPQ) (Additional file 1).
The WPQ evaluated the number of times work was
missed (full and half days), with Work Time Loss defined
as missing ≥ 1 partial or full work day. The principal
causes of absences (health care visits, pain, discomfort,
lack of concentration, visible rash, or medication side ef-
fects), and whether or not extended sick leave, disability,
or use of vacation time was required, was also assessed. In
addition, patients were asked to rate their productivity (ef-
fectiveness) at work during their shingles episode on a
scale of 0–100%.
Health related quality of life
HRQoL was captured using the Euro-QoL (EQ-5D)
questionnaire [20], a generic health status instrument
which evaluates quality of life based on the mea-
surement of five dimensions: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression. A
preference based scale, the EQ-5D assesses each dimen-
sion with three levels of severity; 1 (no problems), 2
(some problems), and 3 (maximum problems). Each
score can then be weighted to adjust for population-
specific preferences in health-care states. For the pur-
poses of this analysis, UK weights, the most validated
weights, were used to convert individual health dimen-
sions scores to a single EQ-5D summary score, with EQ-
5D summary scores closest to 1 indicative of a better
quality of life. The VAS component of the EQ-5D ques-
tionnaire (EQ-5D VAS) also records the patient’s self-
rated health on a horizontal scale, ranging from “worst
imaginable health state” to “best imaginable health
state”. At the baseline visit (Day 0), each patient was re-
quired to complete two EQ-5D questionnaires, one to
assess their usual quality of life prior to HZ onset, and
another to assess their current state of health during the
current HZ episode.
HZ-associated pain
HZ-associated pain was evaluated with the Zoster Brief
Pain Inventory (ZBPI) questionnaire [21] and the Initial
Zoster Impact Questionnaire (IZIQ). The ZBPI is a 9
question HZ-specific questionnaire which evaluates two
components of pain, intensity and interference, on an 11
point Likert scale. More specifically, the ZBPI measures
the presence and location of pain, the severity of the
worst, least, and average pain in the last 24 h, current
pain intensity, use of medications, use of relief medica-
tions, and the interference of pain on general activity,
mood, walking ability, normal work, relations with other
people, sleep and enjoyment of life. The IZIQ, com-
pleted only at baseline, was used to complement the
ZBPI, which was completed at all Study Visits, by asses-
sing pain prior to study enrolment [16–19].
Statistical analysis
Descriptive statistics were produced for all relevant vari-
ables, including the mean and standard deviation for
continuous scale variables, and frequency distributions
for categorical variables. In addition to the total active
population, all analyses were stratified by Work Time
Loss Category (Work Time Loss (WTL) versus No Work
Time Loss (NWTL)). Significance was determined a
priori at p < 0.05, and a statistical trend was defined at
p < 0.150.
For assessment of the correlation between HRQoL
(EQ-5D item scores: domain scores, overall summary
score and VAS) and percentage of work effectiveness,
the Pearson product–moment correlation was used. To
identify predictors of HRQoL, mixed models with re-
peated measures were used, where individual EQ-5D
scores throughout the follow-up period were the
dependent variable, and the following covariates were
considered: Work Time Loss Category (WTL versus
NWTL), age at rash onset, gender, impaired immune
status, presence of HZ complications, severity of rash at
baseline (number of HZ lesions), worst pain score at
baseline (based on the ZBPI “worst pain in the last 24 h”
score), employment status (full-time versus part time),
geographic region, and country income. Impaired im-
mune status was defined as the use of high dose oral
corticosteroids, invasive cancers (with the exception of
CIS and non-melanoma skin cancer), HIV infection/
AIDS, immune deficiency, receipt of chemotherapy for
cancer, prior or concurrent immunosuppressive therapy,
or receipt of immunosuppressive therapy for organ
transplant. Country income categories were determined
according to the 2016 World Bank Income categories:
upper-middle-income economies were defined as those
with a gross national income (GNI) per capita of more
than $4126 but less than $12,735; high-income econ-
omies were defined as those with a GNI per capita of
$12,735 or more [22].
Results
Baseline socio-demographic and disease characteristics
Baseline socio-demographic and disease characteristics
are presented in Tables 1 and 2, respectively, and are
presented overall, as well as stratified by whether or not
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Table 1 Baseline socio-demographic characteristics overall and by Work Time Loss Category
Variable Work time loss category Overallb p-value
Work time lossa No work time loss
Total n, % 247 (57.7) 147 (34.3) 428 -
Age at rash onset, years, mean (SD) 59.0 (7.4) 58.6 (7.1) 58.9 (7. 2) 0.674
Gender, female, n (%) 126 (51.0) 71 (48.3) 217 (50.7) 0.602
Age category at rash onset, years, n (%)
50–59 148 (59.9) 95 (64.6) 263 (61.4)
60–69 79 (32.0) 39 (26.5) 129 (30.1) 0.520
≥ 70 20 (8.1) 13 (8.8) 35 (8.2)
Not Available 0 (0.0) 0 (0.0) 1 (0.2)
Education, n (%)
Primary school or less 54 (21.9) 25 (17.0) 86 (20.1)
High school 77 (31.2) 51 (34.7) 139 (32.5) 0.485
College/University 114 (46.2) 69 (46.9) 199 (46.5)
Not Available 2 (0.8) 2 (1.4) 4 (0.9)
Geographic region, n (%)c
Asia 77 (31.2) 52 (35.4) 140 (32.7)
Latin America 91 (36.8) 33 (22.4) 128 (29.9) 0.010
North America 79 (32.0) 62 (42.2) 160 (37.4)
Country category (income)d
Upper-Middle 94 (38.1) 42 (28.6) 146 (34.1)
High 93 (37.7) 64 (43.5) 171 (40.0) 0.079
Not Available 60 (24.3) 41 (27.9) 111 (25.9)
Employment status, n (%)
Full time 200 (81.0) 112 (76.2) 336 (78.5)
Part time 47 (19.0) 35 (23.8) 92 (21.5) 0.258
Number of hours work overall/week
n 246 146 411
Mean (SD) 39.3 (16.0) 38.3 (17.6) 38.8 (16.5) 0.395
Number of hours part time work/week
n 47 34 89
Mean (SD) 23.3 (11.5) 22.9 (11.7) 23.6 (12.2) 0.939
Number of hours full time work /week
n 199 112 322
Mean (SD) 43.1 (14.4) 43.0 (16.4) 43.0 (15.0) 0.703
Total number persons/household
n 243 145 421
Mean (SD) 2.8 (1.6) 3.0 (1.9) 2.8 (1.7) 0.420
Type of household, n (%)
Apartment 76 (30.8) 48 (32.7) 134 (31.3)
House 170 (68.8) 97 (66.0) 291 (68.0) 0.838
Other 1 (0.4) 1 (0.7) 2 (0.5)
Not Available 0 (0.0) 1 (0.7) 1 (0.2)
Work effectiveness, mean percent, (SD) 50.3 (31.6) 71.4 (27.8) 56.0 (32.0) <0.001
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the patient experienced work time loss (WTL group vs.
NWTL group). Of the 428 patients included in the ana-
lysis, 247 (57.7%) reported losing work time due to their
current HZ episode, with 147 patients (34.3%), reporting
no work time loss. Information on work time loss was
not available for 34 patients (7.9%) (Table 1). Overall,
the mean (SD) age of rash onset was 58.9 (7.2) years,
with over 60% of patients between the ages of 50–59.
No significant differences were reported in baseline
socio-demographic characteristics, with the exception of
geographic region, where the proportion of patients from
Asian, Latin and North American countries differed
across both the WTL and NWTL groups (p = 0.010)
(Table 1). The majority of patients (n = 336; 78.5%) were
employed full time, and 92 (21.5%) were part-time
workers. Regarding work effectiveness, mean (SD) percent
work effectiveness of patients in the WTL group was sig-
nificantly lower compared to the NWTL group at baseline
[50.3 (31.6) vs. 71.4 (27.8); p < 0.001], with a significantly
greater proportion of patients in the WTL group reporting
a decrease in work effectiveness (89.1% in the WTL group
versus, 66.0% in the NWTL group; p < 0.001) (Table 1).
Overall, mean (SD) work time loss reported was 9.1 (15.6)
days.
At baseline, rash was predominately absent or mild in
severity (68.0%, n = 291), with significant differences ob-
served between the WTL and NWTL groups (p = 0.014)
in terms of the proportion of patients reporting no rash
(22.7% WTL vs. 12.2% NWTL), mild rash (43.3% WTL
vs. 58.5% NWTL), moderate rash (19.8% WTL vs. 16.3%
NWTL), and severe rash (14.2% WTL vs. 12.2% NWTL),
and more patients in the NWTL group administered
medication for their HZ episode (9.3% WTL vs. 16.3%
NWTL; p = 0.038) (Table 2). Time from HZ onset was
also significantly longer in the WTL group compared to
the NWTL group [124.2 (458.3) vs. 79.6 (284.2) days;
p < 0.001].
Generally, at baseline, patients in the WTL group re-
ported more severe disease parameters, with significant
differences found for worst pain in the last 24 h [6.2 (2.6)
WTL vs. 5.4 (2.6) NWTL; p = 0.004] and average and
worst pain since rash experience [5.6 (2.3) WTL vs. 4.7
(2.2) NWTL, p =0.002; 7.6 (2.3) WTL vs. 6.5 (2.5) NWTL;
p < 0.001, respectively]; although differences in the propor-
tion of patients experiencing post-rash pain were not sig-
nificant (p = 0.349) (Table 2). In addition, a significant
difference in worst pain (based on the ZBPI “worst pain in
the last 24 h” score) was found between Work Time Loss
Categories, with an overall greater proportion of patients
in the WTL group reporting severe worst pain compared
to the NWTL group (34.8% vs. 22.4%; p = 0.041) (Table 2).
Duration of pain, i.e. from baseline to resolution, was also
significantly higher in the WTL group compared to the
NWTL group [89.9 (193.7) vs. 53.4 (51.4) days; p < 0.001].
No significant differences were found between groups
with regards to prodromal pain. Moreover, at baseline,
patients in the WTL group had significantly lower
(p < 0.001) overall HRQoL (EQ-5D summary score),
greater problems with self-care and usual activities, and
experienced higher pain/discomfort, when compared to
patients in the NWTL group (Table 3). Pooled across all
visits, significantly lower (p < 0.001) scores were seen in
the WTL group for both overall HRQoL (EQ-5D sum-
mary score and VAS) and individual EQ-5D dimensions
(Table 3).
Correlation analyses
Table 4 presents the correlation between percentage of
work effectiveness and all EQ-5D items (dimension
scores, summary score, and the VAS), overall, and by
Work Time Loss Category. All correlation coefficients
(r) reported were found to be statistically significant
(p < 0.001). Overall, percent work effectiveness was nega-
tively correlated with all 5 dimension scores, whereas the
EQ-5D summary score and VAS were positively correlated
with percentage of work effectiveness (r = 0.427 and 0.490,
respectively) suggesting that higher work productivity is
associated with improved HRQoL. Similar results were
observed for the WTL group, although a stronger correl-
ation was observed for percent work effectiveness per the
Table 1 Baseline socio-demographic characteristics overall and by Work Time Loss Category (Continued)
Work effectiveness category, n (%)
100% 20 (8.1) 41 (27.9) 67 (15.7)
50–90% 122 (49.4) 71 (48.3) 206 (48.1) <0.001
10–40% 61 (24.7) 19 (13.0) 87 (20.3)
0% 37 (15.0) 7 (4.8) 10 (2.3)
Not Available 7 (2.8) 9 (6.1) 18 (4.2)
aPatients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, as
assessed by the WPQ
b34 patients did not have information on Work Time Loss Category
cAsia = Korea, Taiwan, Thailand; Latin America = Argentina, Brazil, Costa Rica, Mexico; North America = Canada
dCountry income classifications are based on the 2016 World Bank economic definitions [22]. High Income= Canada, South Korea, Taiwan, Argentina; Upper
Middle Income= Brazil, Costa Rica, Mexico, Thailand
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Table 2 Baseline disease parameters overall and by Work Time Loss Category
Variable Work Time Loss Category Overallb p-value
Work Time Lossa No Work Time Loss
Total n, % 247 (57.7) 147 (34.3) 428 -
Time from HZ onset, days
n 247 147 427
Mean (SD) 124.2 (458.3) 79.6 (284.2) 128.6 (476.6) <0.001
Time from HZ onset - categorical, n (%)
Incident 74 (30.0) 65 (44.2) 154 (36.0)
Prevalent 173 (70.0) 82 (55.8) 273 (63.8) 0.004
Not available 0 (0.0) 0 (0.0) 1 (0.2)
Pain before rash appearance, n (%)
Yes 156 (63.2) 89 (60.5) 260 (60.7)
No 79 (32.0) 52 (35.4) 146 (34.1) 0.520
Not available 12 (4.9) 6 (4.1) 22 (5.1)
Average pain score before rash appearancec
n 155 88 258
Mean (SD) 4.9 (2.6) 4.4 (2.5) 4.7 (2.6) 0.148
Worst pain before rash appearancec
n 154 86 255
Mean (SD) 6.4 (2.6) 5.8 (2.5) 6.2 (2.6) 0.057
Pain since rash appearance, n (%)
Yes 222 (89.9) 130 (88.4) 376 (87.9)
No 14 (5.7) 12 (8.2) 33 (7.7) 0.349
Not available 11 (4.5) 5 (3.4) 19 (4.4)
Average pain since rash appearancec
n 222 129 375
Mean (SD) 5.6 (2.3) 4.7 (2.2) 5.3 (2.3) 0.002
Worst pain since rash appearancec
n 221 128 373
Mean (SD) 7.6 (2.3) 6.5 (2.5) 7.2 (2.5) <0.001
Pain in the last 24 hs
Yes 224 (90.7) 126 (85.7) 380 (88.8)
No 23 (9.3) 20 (13.6) 47 (11.0) 0.178
Not available 0 (0.0) 1 (0.7) 1 (0.2)
Average pain in last 24 hc
n 224 126 380
Mean (SD) 4.5 (2.5) 4.0 (2.3) 4.3 (2.4) 0.062
Worst pain in last 24 hc
n 220 124 372
Mean (SD) 6.2 (2.6) 5.4 (2.6) 5.9 (2.6) 0.004
Worst pain score category, n (%)d
Mild 43 (17.4) 35 (23.8) 83 (19.4)
Moderate 91 (36.8) 55 (37.4) 161 (37.6) 0.041
Severe 86 (34.8) 33 (22.4) 127 (29.7)
Not available 27 (10.9) 24 (16.3) 57 (13.3)
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NWTL group versus the WTL group. This was evident in
particular with regards to the EQ-5D overall summary
score (NWTL: r = 0.402 vs. WTL r = 0.209) and the VAS
(NWTL: r = 0.511 vs. WTL: r = 0.260).
Multivariate analyses
Upon adjusting for Work Time Loss Category, individual
predictors of quality of life (both the EQ-5D summary
score and the VAS) were time since HZ onset, worst
pain score, severity of rash at baseline, geographic re-
gion, and country income (Table 5). Presence of HZ
complications was also identified as a potential predictor
of the VAS. Significant independent predictors of EQ-5D
overall summary score identified in the saturated multi-
variate model are presented in Table 6. Work time loss
was identified as a significant negative predictor of
HRQoL with regards to both the EQ-5D overall sum-
mary score and the VAS (p < 0.001), as was moderate/se-
vere worst pain score compare to mild pain (p < 0.001).
Increased severity of rash was associated with signifi-
cantly higher EQ-5D summary score, (p = 0.042 for mild
vs. no rash; p = 0.206 for moderate vs. no rash; p = 0.017
for severe vs. no rash), whereas country income (high vs.
upper middle income levels) and presence of HZ
complications, were both significant negative predictors
(p = 0.003, and p = 0.007) of the VAS.
Discussion
As reported previously, the results of this analysis dem-
onstrate that shingles has a negative impact on the work
and productive life of individuals [9–11]. Individuals ex-
periencing work time loss reported lower health utility
scores, at baseline and overall, than their non-work time
loss counterparts, with work time loss identified as an
independent negative predictor of both the EQ-5D sum-
mary scores and the VAS (p < 0.001). Decrease in work
effectiveness was also negatively associated with quality
of life overall, and in both the WTL and NWTL groups.
Additional predictors of quality of life identified were
worst pain score, the presence of HZ complications, and
country income (both complications and county income
predictors of the EQ-5D VAS only). Although severity of
rash was identified as a significant predictor of quality of
life, the direction of the prediction is of interest, with
more severe rash associated with improved HRQoL.
This may be explained by the fact that, due to the inclu-
sion of prevalent cases, there may not be a temporal as-
sociation between rash assessment and disease onset.
Thus, it could be argued that patients with no rash were
those for whom rash healing had occurred, and that
consequently, these patients experienced an overall lon-
ger time elapsed since disease onset. As it has been doc-
umented that prolonged pain of HZ has a significant
Table 2 Baseline disease parameters overall and by Work Time Loss Category (Continued)
Severity of rash (number of lesions), n (%)
No rash 56 (22.7) 18 (12.2) 84 (19.6)
Mild (1–20) 107 (43.3) 86 (58.5) 207 (48.4)
Moderate (21–50) 49 (19.8) 24 (16.3) 77 (18.0) 0.014
Severe (>50) 35 (14.2) 18 (12.2) 59 (13.8)
Not available 0 (0.0) 1 (0.7) 1 (0.2)
Impaired immune statuse
Yes 18 (7.3) 9 (6.1) 29 (6.8)
No 229 (92.7) 138 (93.9) 399 (93.2) 0.658
Presence of HZ complication
Yes 80 (32.4) 40 (27.2) 136 (31.8)
No 166 (67.2) 107 (72.8) 291 (68.0) 0.269
Not available 1 (0.4) 0 (0.0) 1 (0.2)
Medication for HZ
Yes 23 (9.3) 24 (16.3) 51 (11.9)
No 224 (90.7) 123 (83.7) 377 (88.1) 0.038
SD standard deviation, HZ Herpes Zoster, CIS carcinoma in situ, HIV human immunodeficiency virus, AIDS acquired immune deficiency syndrome
aPatients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, as
assessed by the WPQ
b34 patients did not have information on Work Time Loss Category
cMeasured on an 11 point Likert scale which ranges from “no pain” (0) to “pain as bad as you can imagine” (11)
dWorst pain score categories are based on the ZPBI “worst pain in the last 24 h” scores: mild worst pain = ZBPI scores 0- ≤ 3; moderate worst pain = ZBPI scores
4- ≤ 7; severe worst pain = ZBPI score ≥8
eDefined as: use of high dose oral corticosteroids, invasive cancers (with the exception of CIS and non-melanoma skin cancer), HIV infection/ AIDS, immune defi-
ciency, chemotherapy for cancer, prior or concurrent immunosuppressive therapy, and therapy for organ transplant
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effect on quality of life [6, 19], the residual post-rash
pain experienced by these patients may have resulted in
the reporting of lower health utility scores compared to
patients assessed earlier in the course of their HZ epi-
sode, when rash manifestation was still evident. In our
analysis, we have tried to adjust for the effect of time
since HZ onset which was not found to have a signifi-
cant impact on quality of life; however, it is possible that
there may be residual confounding.
Overall 57.7% of patients reported missing work for an
average (SD) of 9.1 (15.6) days. Days missed is therefore
higher than that reported by Drolet et al. (3.4 days) and
Singhal et al. (4 days) [9, 10], however discrepancies in
study design may account for these differences: Drolet et
al. evaluated HZ patients within 14 days of rash onset,
whereas this study’s inclusion of prevalent cases may
have resulted in patient recall bias leading to an overesti-
mation of HZ-related work time loss. In addition, at
baseline, a higher proportion of patients in the WTL
group reported a decrease in work effectiveness, indi-
cating that patients who miss work due to their HZ
episode are also less productive, and experience
increased presenteeism.
Importantly, our findings show that patients reporting
work time loss experience lower quality of life as
compared to those not reporting work time loss, inde-
pendently of differences in disease severity and other
potential confounders. This suggests that people, at least
some, consider work loss in their valuation of health
states. Whether the effect of work time loss on quality of
life is due to income loss and/or non-monetary factors
such as psychological factors, could not be evaluated. In
a review paper by Tilling et al., the proportion of pa-
tients who considered monetary losses in health state
valuations when explicit instruction was not given was
found to vary from 6 to 64% across the studies charac-
terized [23]. In the same paper, significant differences in
health care valuations were also observed between
groups with and without instruction to consider income.
Overall, Tiling et al. concluded that considerable incon-
sistencies exist between individuals in regards to consid-
ering income effects when valuing health states [23].
Due to differences in respondent characteristics, severity
of health states values, measurement technique, and
country of conduct, these results, as in the Tilling et al.
review, were not consistent across all studies, and two
Table 4 Correlation between EQ-5D item scores and percentage of work effectiveness overall and by Work Time Loss Category
Variable Work Time Loss Category EQ-5D item scores Correlation coefficient b P-value
Percent work effectivenessc Overall Mobility −0.265 <0.001
Self-Care −0.243 <0.001
Usual activities −0.401 <0.001
Pain/Discomfort −0.396 <0.001
Anxiety/Depression −0.331 <0.001
EQ-5D summary scores based on UK weight 0.427 <0.001
EQ-5D VAS 0.490 <0.001
Mobility −0.238 <0.001
Self-Care −0.158 <0.001
Usual activities −0.323 <0.001
No Work Time Loss Pain/Discomfort −0.356 <0.001
Anxiety/Depression −0.329 <0.001
EQ-5D summary scores based on UK weight 0.402 <0.001
EQ-5D VAS 0.511 <0.001
Mobility −0.148 <0.001
Self-Care −0.162 <0.001
Usual activities −0.245 <0.001
Work Time Lossa Pain/Discomfort −0.161 <0.001
Anxiety/Depression −0.140 <0.001
EQ-5D summary scores based on UK weight 0.209 <0.001
EQ-5D VAS 0.260 <0.001
WPQ Work and Productivity Questionnaire, VAS visual analogue scale
aPatients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, or at any
of the follow-up visits (Visits 2–10) as assessed by the WPQ
bCorrelation coefficient was calculated based on Pearson’s correlation measure
cPooled over time (Visits 1–10)
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were identified in which a majority of respondents did
consider income [24, 25]. However, the two studies iden-
tified report that even with explicit instruction, the ef-
fects on income on health care valuations are disputable:
Shiroiwa et al. found no significant differences in utility
scores between individuals receiving no instruction re-
garding income, individuals instructed to consider
income reduction, and individuals instructed to assume
compensation for lost income [25], and Krol et al. found
that explicit instruction on the inclusion of income ef-
fects had only some effect on time trade-off (TTO) valu-
ations [24]. This suggests that the effect of lost income
on utility scores is multifaceted, as it may involve social
aspects such as human relationships and self-fulfillment,
Table 5 Repeated measures mixed model analysis assessing individual predictors of the EQ-5D summary score and EQ-5D VAS
EQ-5D Item
EQ-5D overall summary score EQ-5D VAS
Predictor Estimatea SD 95% CI for estimate p-value Estimatea SD 95% CI for estimate p-value
Work Time Loss Category
Work Time Lossb vs. No Work Time Loss −0.234 0.010 −0.254, −0.215 <0.001 −16.92 0.755 −18.40, −15.44 <0.001
Time from HZ onset - categorical
Prevalent vs. incident −0.049 0.014 −0.076, −0.022 <0.001 −3.811 1.339 −6.442, −1.181 0.005
Age category at rash onset, yearsc
60–69 vs. 50–59 −0.002 0.015 −0.032, 0.028 0.898 −1.562 1.465 −4.441, 1.318 0.287
≥ 70 vs. 50–59 −0.042 0.026 −0.092, 0.008 0.100 −2.785 2.472 −7.643, 2.073 0.260
Worst Pain Categoryc,d
Moderate vs. mild −0.084 0.013 −0.111, −0.058 <0.001 −8.842 1.075 −10.95, −6.732 <0.001
Severe vs. mild −0.287 0.018 −0.323, −0.251 <0.001 −14.08 1.447 −16.92, −11.24 <0.001
Severity of rash (number of lesions)c
Mild (1–20) vs.no rash 0.109 0.017 0.074, 0.143 <0.001 10.646 1.707 7.292, 14.000 <0.001
Moderate (21–50) vs. no rash 0.100 0.021 0.058, 0.141 <0.001 8.892 2.064 4.837, 12.947 <0.001
Severe (>50) vs. no rash 0.095 0.024 0.049, 0.142 <0.001 9.684 2.278 5.207, 14.160 <0.001
Genderc
Male vs. female −0.005 0.013 −0.032, 0.021 0.691 0.833 1.295 −1.711, 3.377 0.520
Impaired immune statusc, e
Yes vs. no −0.034 0.025 −0.084, 0.016 0.181 −1.876 2.472 −6.734, 2.983 0.448
Presence of complications from HZc
Yes vs. no −0.012 0.014 −0.040, 0.016 0.400 −5.016 1.370 −7.707, −2.324 <0.001
Employment statusc
Full time vs. part time 0.008 0.016 −0.024, 0.040 0.612 −1.919 1.574 −5.011, 1.173 0.223
Geographic regionc,f
Latin America vs. Asia 0.030 0.017 −0.004, 0.064 0.191 3.245 1.628 0.047, 6.443 0.098
North America vs. Asia −0.043 0.017 −0.076, −0.010 0.011 −5.146 1.583 −8.257, −2.035 0.001
Country category (income)c, g
High vs. Upper Middle −0.052 0.014 −0.079, −0.026 <0.001 −6.616 1.290 −9.151, −4.081 <0.001
SD standard deviation, CI confidence interval, HZ Herpes Zoster, WPQ Work and Productivity Questionnaire, ZBPI Zoster Brief Pain Inventory, VAS visual analogue
scale, CIS carcinoma in situ, HIV human immunodeficiency virus, AIDS acquired immune deficiency syndrome
aThe estimate is the relative effect of the predictor on EQ-5D scores compared to the reference group
bPatients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, or at any
of the follow-up visits (Visits 2–10) as assessed by the WPQ
cPredictors were adjusted by Work Time Loss Category
dWorst pain score categories are based on the ZBPI “worst pain in the last 24 h” scores: mild worst pain = ZBPI scores 0- ≤ 3; moderate worst pain = ZBPI scores
4- ≤ 7; severe worst pain = ZBPI score ≥8
e Defined as: use of high dose oral corticosteroids, invasive cancers (with the exception of CIS and non-melanoma skin cancer), HIV infection/ AIDS, immune
deficiency, chemotherapy for cancer, prior or concurrent immunosuppressive therapy, and therapy for organ transplant
fAsia = Taiwan, Thailand, South Korea; Latin America = Argentina, Brazil, Costa Rica; Mexico; North America = Canada
gCountry income classifications are based on the 2016 World Bank economic definitions [22]. High Income= Canada, South Korea, Taiwan, Argentina; Upper
Middle Income= Brazil, Costa Rica, Mexico, Thailand
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rendering the effects of double counting in calculating
cost-effectiveness negligible [25].
A limitation of the current analysis is that, due to the
inclusion of prevalent cases, time since disease onset
varied across patients, and may have led to recall bias in
the assessment of work time loss since rash onset and
the presence of prodromal pain. Furthermore, disease
misclassification cannot be ruled out, as laboratory con-
firmation of VZV was not protocol-mandated. Finally, it
is possible that selection bias towards including more se-
vere HZ cases may have been introduced due to the fact
that the patient population comprised of patients who
sought out medical attention for their HZ episode.
Conclusions
The results of this study demonstrate that HZ-related
reductions in work effectiveness and work time have a
negative effect on the quality of life of actively employed
individuals, independently of differences in disease se-
verity and other potential confounders. However, it
remains to be determined whether patients consider
reductions in income when valuating health care
states, as the results of studies assessing the un-
prompted inclusion of the effects of income have re-
ported conflicting results [25, 26]. In fact, the revised
recommendations put forth by the Panel on Cost-
Effectiveness in Health and Medicine, in a complete
methodological shift, affirm that effects on productiv-
ity are unlikely to be captured in the denominator of
most preference-based measures, citing inconclusive
evidence [15]. Instead, in reference case analyses
conducted under the societal perspective, the Panel
advocates for the inclusion of these effects in the
numerator of the ICER despite uncertainty with
respect to the risk of double counting [15].
Additional file
Additional file 1: Work and Productivity Questionnaire. (PDF 14 kb)
Table 6 Saturated multivariate repeated measures mixed model assessing independent predictors of the EQ-5D summary score and
EQ-5D VAS
EQ-5D Item
EQ-5D overall summary scores EQ-5D VAS
Predictor Estimatea SD 95% CI for estimate p-value Estimatea SD 95% CI for estimate p-value
Work Time Loss Category
Work Time Lossb vs. No Work Time Loss −0.102 0.014 −0.129, −0.074 <0.001 −6.511 1.109 −8.687, −4.336 <0.001
Time from HZ onset - categorical
Prevalent vs. incident −0.016 0.019 −0.052, 0.020 0.387 −0.871 1.754 −4.320, 2.578 0.620
Worst Pain Categoryc
Moderate vs. mild −0.083 0.014 −0.109, −0.056 <0.001 −8.761 1.079 −10.88, −6.643 <0.001
Severe vs. mild −0.290 0.018 −0.326, −0.254 <0.001 −14.40 1.445 −17.23, −11.56 <0.001
Severity of rash (number of lesions)
Mild (1–20) vs. no rash 0.044 0.021 0.002, 0.086 0.042 4.150 2.128 0.035, 8.334 0.052
Moderate (21–50) vs. no rash 0.035 0.028 −0.019, 0.090 0.206 3.755 2.667 −1.489, 8.999 0.160
Severe (>50) vs. no rash 0.070 0.029 0.012, 0.128 0.017 4.621 2.865 −1.014, 10.255 0.108
Country category (income)d
High vs. Upper Middle −0.027 0.033 −0.091, 0.038 0.413 −8.532 2.902 −14.24, −2.828 0.003
Geographic regione
Latin America vs. Asia 0.021 0.032 −0.042, 0.083 0.513 −2.793 2.839 −8.374, 2.788 0.326
North America vs. Asia 0.005 0.024 −0.043, 0.052 0.851 1.428 2.253 −3.001, 5.856 0.527
Presence of complications of HZ
Yes vs. no - - - - −4.509 1.654 −7.761, −1.257 0.007
SD standard deviation, CI confidence interval, VAS visual analogue scale, WPQ Work and Productivity Questionnaire
aThe estimate is the relative effect of the predictor on EQ-5D scores compared to the reference group
b Patients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, or at any
of the follow-up visits (Visits 2–10) as assessed by the WPQ
c Worst pain categories are based on the ZBPI “worst pain in the last 24 h” scores: mild worst pain = ZBPI scores 0- ≤ 3; moderate worst pain = ZBPI scores 4- ≤ 7;
severe worst pain = ZBPI score ≥8
d Country income classifications are based on the 2016 World Bank economic definitions [22]. High Income= Canada, South Korea, Taiwan, Argentina; Upper
Middle Income= Brazil, Costa Rica, Mexico, Thailand
e Asia = Taiwan, Thailand, South Korea; Latin America = Argentina, Brazil, Costa Rica; Mexico; North America = Canada
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